OWKIN Growth, Revenue, Number of Employees and Funding
Revenue & Financials
- OWKIN received $Undisclosed in venture funding in March 2019. 0
- OWKIN's total funding is $11M.
- OWKIN has 82 Employees.
- OWKIN grew their employee count by 141% last year.
- OWKIN currently has 5 job openings.
What Is OWKIN?
OWKIN was co-founded in 2016 by Thomas Clozel, MD, a clinical research doctor and former assistant professor in clinical hematology and Gilles Wainrib, PhD, a pioneer in the field of Artificial Intelligence in biology. OWKIN is an AI startup that uses machine learning to augment medical and biology research. Our proprietary platform, OWKIN Socrates, uses machine learning technology to integrate biomedical images, genomics and clinical data to discover biomarkers and mechanisms associated with diseases and treatment outcomes. Our team is international, multidisciplinary with incredible talent in machine learning, medicine and business. Our data scientists are among the best in the world, with several Kaggle Masters (top global 100), a DREAM Challenge top performer, and publications in ICML, NIPS and other top scientific journals. OWKIN develops scientific collaborations with top-tier medical institutions such as Mount Sinai, Inserm, Institut Curie and the Léon Bérard Center, and partners with leading pharmaceutical companies, including Amgen, Roche, and Ipsen. OWKIN has developed a state-of-the-art federated learning technology in healthcare to overcome the data sharing problem, building collective intelligence from distributed data at scale while preserving data privacy and security.keywords:N/A
Number of Employees
Employee Growth %
|Name||Revenue||Number of Employees||Employee Growth||Total Funding|
|North Central B...||N/A||249||6%|
|IDEX Health & S...||$10.5M||69||1%|
Owkin, a NYC-based company which builds machine learning technologies and infrastructure to enable medical research, received a funding
Owkin, a Paris-based startup backed by Google Ventures, is also using it to predict patients' resistance to different treatments and drugs,
A year after raising a modest Series A to develop its predictive analytics tech for drug discovery, Owkin has brought in more high profile